187 related articles for article (PubMed ID: 34296055)
1. Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis.
Kok PS; Yoon WH; Lord S; Marschner I; Friedlander M; Lee CK
JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34296055
[TBL] [Abstract][Full Text] [Related]
2. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
3. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
[TBL] [Abstract][Full Text] [Related]
4. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
5. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
[TBL] [Abstract][Full Text] [Related]
6. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors' efficacy: a systematic review and meta-analysis of randomized studies.
Amoroso V; Gallo F; Alberti A; Paloschi D; Ferrari Bravo W; Esposito A; Cosentini D; Grisanti S; Pedersini R; Petrelli F; Berruti A
ESMO Open; 2023 Apr; 8(2):100787. PubMed ID: 36842300
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang ZX; Wu HX; Xie L; Wang YN; Yang LP; He MM; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
JAMA Netw Open; 2019 May; 2(5):e193433. PubMed ID: 31050784
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive evaluation of surrogate endpoints to predict overall survival in trials with PD1/PD-L1 immune checkpoint inhibitors plus chemotherapy.
Villacampa G; Cresta Morgado P; Navarro V; Viaplana C; Dienstmann R
Cancer Treat Rev; 2023 May; 116():102542. PubMed ID: 37003083
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
10. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
11. Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials.
Li J; He Q; Yu X; Khan K; Weng X; Guan M
Cancer Manag Res; 2019; 11():1623-1629. PubMed ID: 30863172
[TBL] [Abstract][Full Text] [Related]
12. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
[TBL] [Abstract][Full Text] [Related]
14. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.
Sala I; Pagan E; Pala L; Oriecuia C; Musca M; Specchia C; De Pas T; Cortes J; Giaccone G; Postow M; Gelber RD; Bagnardi V; Conforti F
Front Immunol; 2024; 15():1340979. PubMed ID: 38348030
[TBL] [Abstract][Full Text] [Related]
15. Relationship Between Progression-Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD-1/PD-L1 Immune Checkpoint Blockade: A Meta-Analysis.
Ye J; Ji X; Dennis PA; Abdullah H; Mukhopadhyay P
Clin Pharmacol Ther; 2020 Dec; 108(6):1274-1288. PubMed ID: 32564368
[TBL] [Abstract][Full Text] [Related]
16. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
[TBL] [Abstract][Full Text] [Related]
17. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
Goring S; Varol N; Waser N; Popoff E; Lozano-Ortega G; Lee A; Yuan Y; Eccles L; Tran P; Penrod JR
Lung Cancer; 2022 Aug; 170():122-132. PubMed ID: 35767923
[TBL] [Abstract][Full Text] [Related]
18. Impact of treatment timing and sequence of immune checkpoint inhibitors and anti-angiogenic agents for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Matsumoto K; Shiroyama T; Kuge T; Miyake K; Yamamoto Y; Yoneda M; Yamamoto M; Naito Y; Suga Y; Fukushima K; Koyama S; Iwahori K; Hirata H; Nagatomo I; Takeda Y; Kumanogoh A
Lung Cancer; 2021 Dec; 162():175-184. PubMed ID: 34823108
[TBL] [Abstract][Full Text] [Related]
19. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis.
Zhu GL; Yang KB; Tang SQ; Peng L
Cancer Med; 2021 Dec; 10(23):8272-8287. PubMed ID: 34668660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
